Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression

References

• Vassiliki’ Coutsoumbas G, Zagnoni S, Corona G, et al. Sodium-glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes? Eur Heart J Suppl. 2020;22(Suppl L):L66–L71. doi: 10.1093/eurheartj/suaa138
   PubMed Web of Science ®Google Scholar
• Rahelić D, Javor E, Lucijanić T, et al. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Ann Med. 2017;49(1):51–62. doi: 10.1080/07853890.2016.1226514
   PubMed Web of Science ®Google Scholar
• Koufakis T, Mustafa OG, Ajjan RA, et al. From skepticism to hope: The evolving concept of the initiation and use of sodium-glucose cotransporter 2 inhibitors in hospitalized patients. Drugs. 2022;82(9):949–955. doi: 10.1007/s40265-022-01730-2
   PubMed Web of Science ®Google Scholar
• Mascolo A, Di Napoli R, Balzano N, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med. 2022;9:1010693. doi: 10.3389/fcvm.2022.1010693
   PubMed Web of Science ®Google Scholar
• Ramani J, Shah H, Vyas VK, et al. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. Eur J Med Chem Rep. 2022;6:100074. doi: 10.1016/j.ejmcr.2022.100074
   Google Scholar
• Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503–514. doi: 10.1007/s00592-018-1116-0
   PubMed Web of Science ®Google Scholar
• Younes AM, Salem M, Maraey A, et al. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and meta-analysis. Int J Cardiol. 2022;366:51–56. doi: 10.1016/j.ijcard.2022.06.059
   PubMed Web of Science ®Google Scholar
• Cao H, Rao X, Jia J, et al. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2023;60(3):325–335. doi: 10.1007/s00592-022-01989-7
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hsu SP, Chiu YL, et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022;12(10):e060655. doi: 10.1136/bmjopen-2021-060655
   PubMed Web of Science ®Google Scholar
• Bapir R, Bhatti KH, Eliwa A, et al. Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis. Arch Ital Urol Androl. 2023;95(2):11509. doi: 10.4081/aiua.2023.11509
   PubMedGoogle Scholar
• Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e022577. doi: 10.1136/bmjopen-2018-022577
   PubMed Web of Science ®Google Scholar
• Zheng Z, He D, Chen J, et al. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43(4):209–225. doi: 10.1007/s40261-023-01256-9
   PubMed Web of Science ®Google Scholar
• Li J, Zhu C, Liang J, et al. Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis. Front Pharmacol. 2023;14:1303694. doi: 10.3389/fphar.2023.1303694
   PubMed Web of Science ®Google Scholar
• Jang HY, Kim IW, Oh JM. Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data. Front Pharmacol. 2022;13:928121. doi: 10.3389/fphar.2022.928121
   PubMed Web of Science ®Google Scholar
• Uitrakul S, Aksonnam K, Srivichai P, et al. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines (Basel). 2022;9(12):59. doi: 10.3390/medicines9120059
   PubMedGoogle Scholar
• Li T, Puhan MA, Vedula SS, et al. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9(1):79. doi: 10.1186/1741-7015-9-79
   PubMedGoogle Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784. doi: 10.7326/M14-2385
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2 October 2018):d5928. doi: 10.1136/bmj.d5928
   PubMedGoogle Scholar
• Fragkos KC, Tsagris M, Frangos CC. Publication bias in meta-analysis: confidence intervals for rosenthal’s fail-safe number. Int Sch Res Not. 2014;2014:825383. doi: 10.1155/2014/825383
   PubMedGoogle Scholar
• Gjerdevik M, Heuch I. Improving the error rates of the begg and mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol. 2014;14(1):109. doi: 10.1186/1471-2288-14-109
   PubMedGoogle Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi: 10.1002/sim.1186
   PubMed Web of Science ®Google Scholar
• EpiGear International. [cited 2024 Jan 6]. Available from: https://www.epigear.com/index.htm
   Google Scholar
• GRADE handbook. Introduction to GRADE handbook. [cited 2024 Jan 12]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html
   Google Scholar
• Li CX, Liu TT, Zhang Q, et al. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies. Front Pharmacol. 2023;14:1275060. doi: 10.3389/fphar.2023.1275060
   PubMed Web of Science ®Google Scholar
• Wallace BC, Lajeunesse MJ, Dietz G, et al. Open MEE: Intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol. 2017;8(8):941–947. doi: 10.1111/2041-210X.12708
   Web of Science ®Google Scholar
• Schandelmaier S, Briel M, Varadhan R, et al. Development Of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192(32):E901–E906. doi: 10.1503/cmaj.200077
   PubMed Web of Science ®Google Scholar
• Geerlings SE, Brouwer EC, Gaastra W, et al. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48(6):535–539. doi: 10.1099/00222615-48-6-535
   PubMed Web of Science ®Google Scholar
• Ignatova N, Abidullina A, Streltsova O, et al. Effect of pH, norepinephrine and glucose on metabolic and biofilm activity of uropathogenic microorganisms. Microorganisms. 2023;11(4):862. doi: 10.3390/microorganisms11040862
   PubMed Web of Science ®Google Scholar
• Sabih A, Leslie SW. Complicated urinary tract infections. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. [cited 2024 Apr 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK436013/
   Google Scholar
• Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. doi: 10.1038/s41598-017-02733-w
   PubMedGoogle Scholar
• Hirji I, Guo Z, Andersson SW, et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK general practice research database (GPRD. J Diabetes Complicat. 2012;26(6):513–516. doi: 10.1016/j.jdiacomp.2012.06.008
   PubMed Web of Science ®Google Scholar
• Han Z, He Y, Li X, et al. Insights into the impact of sodium-glucose cotransporter 2 inhibition on urinary tract malignancy: a two-sample mendelian randomization. Diab Obes Metab. 2024;26(5):1986–1989. doi: 10.1111/dom.15490
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Wadhwa R, Kapoor D, et al. High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among indian patients with type 2 diabetes. Indian J Endocrinol Metab. 2019;23(1):9–13. doi: 10.4103/ijem.IJEM_244_18
   PubMedGoogle Scholar
• Wilson RM, Tomlinson DR, Reeves WG. Neutrophil sorbitol production impairs oxidative killing in diabetes. Diabet Med. 1987;4(1):37–40. doi: 10.1111/j.1464-5491.1987.tb00825.x
   PubMed Web of Science ®Google Scholar
• Saha S, Saha S, Gayen M. Treatment-duration-wise harm profile of insulin-sodium-glucose co-transporter inhibitor co-treatment in type 1 diabetes mellitus patients. J Diabetes Metab Disord. 2023;22(1):673–701. doi: 10.1007/s40200-023-01192-7
   PubMed Web of Science ®Google Scholar
• Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022;65(12):2000–2010. doi: 10.1007/s00125-022-05773-8
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230. doi: 10.1007/s40265-019-1057-0
   PubMed Web of Science ®Google Scholar
• Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med. 2017;129(7):686–697. doi: 10.1080/00325481.2017.1342509
   PubMed Web of Science ®Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730–1735. doi: 10.2337/dc15-0355
   PubMed Web of Science ®Google Scholar
• Boye KS, Lage MJ, Thieu V, et al. Obesity and glycemic control among people with type 2 diabetes in the United States: a retrospective cohort study using insurance claims data. J Diabetes Complications. 2021;35(9):107975. doi: 10.1016/j.jdiacomp.2021.107975
   PubMed Web of Science ®Google Scholar
• Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253–273. doi: 10.1128/CMR.00076-09
   PubMed Web of Science ®Google Scholar
• Bartolo C, Hall V, Friedman ND, et al. Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports. BMC Infect Dis. 2021;21(1):284. doi: 10.1186/s12879-021-05982-3
   PubMed Web of Science ®Google Scholar
• Fralick M, MacFadden DR. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. Diab Obes Metab. 2020;22(5):755–758. doi: 10.1111/dom.13959
   PubMed Web of Science ®Google Scholar
• Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin angiotensin system. Int J Mol Sci. 2019;20(3):1–13. doi: 10.3390/ijms20030629
   Web of Science ®Google Scholar
• Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509–1515. doi: 10.1001/jamainternmed.2018.4204
   PubMed Web of Science ®Google Scholar
• Czajkowski K, Broś-Konopielko M, Teliga-Czajkowska J. Urinary tract infection in women. Prz Menopauzalny. 2021;20(1):40–47. doi: 10.5114/pm.2021.105382
   PubMedGoogle Scholar
• Lin YH, Lin CH, Huang YY, et al. Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study. Diabet Res Clin Pract. 2022;186:109816. doi: 10.1016/j.diabres.2022.109816
   PubMed Web of Science ®Google Scholar
• McGovern AP, Hogg M, Shields BM, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238. doi: 10.1136/bmjdrc-2020-001238
   PubMed Web of Science ®Google Scholar
• Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diab Obes Metab. 2019;21(2):434–438. doi: 10.1111/dom.13531
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Office on women’s health. Urinary tract infections. [cited 2024 Apr 28]. Available from: https://www.womenshealth.gov/a-z-topics/urinary-tract-infections#:~:text=Women%20get%20UTIs%20up%20to%2030%20times%20more%20often%20than%20men%20do.&text=Also%2C%20as%20many%20as%204,one%20more%20within%20six%20months.&text=Women%20get%20UTIs%20more%20often,is%20shorter%20than%20a%20man’s
   Google Scholar
• Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK general practice research database. J Diabetes Complicat. 2012;26(6):501–505. doi: 10.1016/j.jdiacomp.2012.06.012
   PubMed Web of Science ®Google Scholar